Study Suggests Chemotherapy Diminishes Fertility in Breast Cancer Patients
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Study Suggests Chemotherapy Diminishes Fertility in Breast Cancer Patients

BOSTON -- May 30, 2008 -- According to a study led by investigators at the Dana-Farber Cancer Institute, Boston, Massachusetts, premenopausal breast cancer survivors treated with chemotherapy following surgery were more likely to have diminished ovarian reserve compared with women who have never had breast cancer. These findings will be presented at the American Society of Clinical Oncology (ASCO) 44th Annual Meeting, May 30 to June 3, in Chicago, Illinois.

The researchers analysed markers of ovarian reserve in 20 premenopausal breast cancer patients who had been treated with adjuvant chemotherapy, who were 1 or more years out from their diagnosis, and who had no evidence of recurrence. This group was compared with a control group of 20 like-aged women without a history of the disease.

The evaluation involved 5 tests conducted 2, 3, or 4 days after a menstrual cycle to assess the ovaries' physical condition, hormone levels, and a compound involved in the menstrual cycle. In 4 of the 5 tests, the breast cancer survivors had a worse ovarian reserve than did the control group. The other test showed no major difference between the 2 groups.

"These findings may have important implications for women who are interested in having children after receiving chemotherapy," said Ann Partridge, MD, MPH, Dana-Farber Cancer Institute, who led the study. "Studies that track breast cancer survivors following treatment are needed to determine the predictive value of these tests for pregnancy."

SOURCE: Dana-Farber Cancer Institute

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities